Literature DB >> 7754629

Patient selection and treatment of peritoneal carcinomatosis from colorectal and appendiceal cancer.

P H Sugarbaker1.   

Abstract

Colorectal cancer is a disease process that disseminates through lymphatic channels, through hematogenous routes, and by invasion through the bowel wall. These mechanisms result in lymph node metastases, liver metastases, and peritoneal seeding. Although lymphatic and venous dissemination requires an invasive local process, peritoneal seeding may occur with both high grade and low grade malignancies. Cancer dissemination that causes liver and lymphatic metastases occurs prior to surgical resection of the primary colorectal cancer. Peritoneal seeding and seeding of the resection site (local recurrence) may also occur as a result of the surgical trauma that accompanies resection of the primary lesion. Leakage of malignant cells from transected lymphatic channels may be the mechanism of this intraoperative intraperitoneal cancer dissemination. To limit the progression of peritoneal seeding and to treat large volume, low grade intraabdominal tumor deposits, combinations of cytoreductive surgery and intraperitoneal chemotherapy have been successfully employed. Selection factors that correlate with long-term benefit are (1) low grade of malignancy, (2) lack of lymph node or liver metastases, and (3) treatment of low volume disease. For patients with moderate or high grade colorectal cancer, only a low volume of disease can be treated successfully. For patients with low grade cancer, peritonectomy procedures are used to achieve minimal residual disease before initiating the intraperitoneal chemotherapy. In properly selected patients, peritoneal carcinomatosis from colorectal and appendiceal cancer is a treatable condition that may result in long-term disease-free survival.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7754629     DOI: 10.1007/BF00308632

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  4 in total

1.  Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies.

Authors:  P H Sugarbaker; T Graves; E A DeBruijn; W J Cunliffe; R E Mullins; W E Hull; L Oliff; P Schlag
Journal:  Cancer Res       Date:  1990-09-15       Impact factor: 12.701

2.  Mechanisms of relapse for colorectal cancer: implications for intraperitoneal chemotherapy.

Authors:  P H Sugarbaker
Journal:  J Surg Oncol Suppl       Date:  1991

Review 3.  Gastrointestinal malignancy: rationale for adjuvant therapy using early postoperative intraperitoneal chemotherapy.

Authors:  W J Cunliffe; P H Sugarbaker
Journal:  Br J Surg       Date:  1989-10       Impact factor: 6.939

4.  Morbidity and mortality of cytoreductive surgery and intraperitoneal chemotherapy.

Authors:  J Esquivel; J Vidal-Jove; M A Steves; P H Sugarbaker
Journal:  Surgery       Date:  1993-06       Impact factor: 3.982

  4 in total
  19 in total

1.  Experimental assessment of tumor growth and dissemination of a microscopic peritoneal carcinomatosis after CO2 peritoneal insufflation or laparotomy.

Authors:  E Fondrinier; M Boisdron-Celle; A Chassevent; G Lorimier; E Gamelin
Journal:  Surg Endosc       Date:  2001-05-07       Impact factor: 4.584

2.  Wound recurrence after laparoscopic colectomy for cancer. New rationale for intraoperative intraperitoneal chemotherapy.

Authors:  P Jacquet; P H Sugarbaker
Journal:  Surg Endosc       Date:  1996-03       Impact factor: 4.584

Review 3.  Understanding molecular mechanisms in peritoneal dissemination of colorectal cancer : future possibilities for personalised treatment by use of biomarkers.

Authors:  E M V de Cuba; R Kwakman; M van Egmond; L J W Bosch; H J Bonjer; G A Meijer; E A te Velde
Journal:  Virchows Arch       Date:  2012-07-24       Impact factor: 4.064

4.  Is ascites CEA a risk factor for peritoneal carcinomatosis in colorectal cancer?: a long-term follow-up study.

Authors:  Byung Chul Kim; Jung Hoon Bae; Sun Min Park; Dae Youn Won; In Kyu Lee
Journal:  Int J Colorectal Dis       Date:  2019-12-05       Impact factor: 2.571

5.  Laparoscopic adrenalectomy by the anterior transperitoneal approach: results of 108 operations in unselected cases.

Authors:  E Lezoche; M Guerrieri; A M Paganini; F Feliciotti; P Zenobi; F Antognini; F Mantero
Journal:  Surg Endosc       Date:  2000-10       Impact factor: 4.584

6.  Risk factors for recurrence following complete cytoreductive surgery and HIPEC in colorectal cancer-derived peritoneal surface malignancies.

Authors:  Ingmar Königsrainer; Philipp Horvath; Florian Struller; Viola Forkl; Alfred Königsrainer; Stefan Beckert
Journal:  Langenbecks Arch Surg       Date:  2013-03-01       Impact factor: 3.445

7.  Experience after 100 patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Ingmar Königsrainer; Derek Zieker; Jörg Glatzle; Olivia Lauk; Julia Klimek; Stephan Symons; Björn Brücher; Stefan Beckert; Alfred Königsrainer
Journal:  World J Gastroenterol       Date:  2012-05-07       Impact factor: 5.742

Review 8.  Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: where are we?

Authors:  Ingmar Königsrainer; Stefan Beckert
Journal:  World J Gastroenterol       Date:  2012-10-14       Impact factor: 5.742

9.  Iterative cytoreductive surgery associated with hyperthermic intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis of colorectal origin with or without liver metastases.

Authors:  Reza Kianmanesh; Stefano Scaringi; Jean-Marc Sabate; Benjamin Castel; Nathalie Pons-Kerjean; Benoit Coffin; Jean-Marie Hay; Yves Flamant; Simon Msika
Journal:  Ann Surg       Date:  2007-04       Impact factor: 12.969

Review 10.  The Role of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Appendiceal Tumors and Colorectal Adenocarcinomas.

Authors:  Michael Kuncewitch; Edward A Levine; Perry Shen; Konstantinos I Votanopoulos
Journal:  Clin Colon Rectal Surg       Date:  2018-09-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.